@article{132a58bdad0d42fc85ad878bffe24b14,
title = "Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018",
abstract = "Background: An updated understanding of allergic contact dermatitis is needed, particularly in children. Objectives: To compare positive and clinically relevant reactions in children versus adults referred for patch testing. Methods: Retrospective analysis of 1871 children and 41,699 adults from the North American Contact Dermatitis Group (NACDG) from 2001-2018. Results: Both final diagnosis of allergic contact dermatitis (55.2% versus 57.3%; chi square, P = .0716) and prevalence of ≥ 1 currently relevant reaction to a NACDG screening allergen (49.2% vs 52.2%; P = .1178) were similar between children and adults. Currently in children, the most common relevant allergens were nickel sulfate (17.3%), hydroperoxides of linalool (7.8%), methylisothiazolinone (7.7%), cobalt chloride (7.0%), and fragrance mix I (4.9%). Approximately a fifth of children had a positive reaction to a non-NACDG allergen. Conclusion: Over half of children referred for patch testing were diagnosed with allergic contact dermatitis. The most common relevant allergens in children were nickel sulfate, cobalt chloride, and hydroperoxides of linalool. Twenty percent of children had at least 1 positive reaction to allergens/substances not on the NACDG screening series, underscoring the need for comprehensive testing.",
author = "Silverberg, {Jonathan I.} and Alexander Hou and Warshaw, {Erin M.} and DeKoven, {Joel G.} and Maibach, {Howard I.} and Belsito, {Donald V.} and Zug, {Kathryn A.} and Taylor, {James S.} and Denis Sasseville and Dunnick, {Cory A.} and Houle, {Marie Claude} and Atwater, {Amber R.} and Reeder, {Margo J.} and DeLeo, {Vincent A.} and Pratt, {Melanie D.} and Fowler, {Joseph F.} and Zirwas, {Matthew J.} and Marks, {James G.}",
note = "Funding Information: This study was supported by resources and use of facilities at the Minneapolis Veterans Affairs Medical Center. The contents do not represent the views of the US Department of Veterans Affairs or the US Government. Dr Sasseville receives royalties from UpToDate (Wolters Kluwer Health). Dr Taylor owns noncontrolling common stock in Cigna, Merck, Johnson and Johnson, Astra Zeneca, and Opko Health; is a member of the Cosmetic Ingredient Review Steering Committee; and has a nondependent child who is employed by Pfizer. Dr Warshaw has served as a consultant for Wen by Chaz Dean and Noven Pharmaceuticals and is grant funded by Wen by Chaz Dean. Dr Atwater received a Pfizer Independent Grant for Learning & Change and has consulted for Henkel. Funding sources: None. Funding Information: This study was supported by resources and use of facilities at the Minneapolis Veterans Affairs Medical Center. The contents do not represent the views of the US Department of Veterans Affairs or the US Government. Dr Sasseville receives royalties from UpToDate (Wolters Kluwer Health). Dr Taylor owns noncontrolling common stock in Cigna, Merck, Johnson and Johnson, Astra Zeneca, and Opko Health; is a member of the Cosmetic Ingredient Review Steering Committee; and has a nondependent child who is employed by Pfizer. Dr Warshaw has served as a consultant for Wen by Chaz Dean and Noven Pharmaceuticals and is grant funded by Wen by Chaz Dean . Dr Atwater received a Pfizer Independent Grant for Learning & Change and has consulted for Henkel. Publisher Copyright: {\textcopyright} 2021 American Academy of Dermatology, Inc.",
year = "2022",
month = apr,
doi = "10.1016/j.jaad.2021.07.030",
language = "English (US)",
volume = "86",
pages = "818--826",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",
}